Abstracts tagged "meta-analysis"

Abstract Number: 2255 • ACR Convergence 2025
Diagnostic Accuracy of Anti-Carbamylated Protein Antibodies in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Pannathorn Nakaphan¹, Patavee Pajareya², Priabprat Jansem³, Somkiat Phutinart², Nattanicha Chaisrimaneepan⁴ and Noppachai Siranart², ¹Department of Internal Medicine, Weiss Memorial Hospital, Chicago, IL, ²Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, ³Department of Psychiatry, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand, ⁴Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX
Background/Purpose: Anti-carbamylated protein antibodies (anti-CarP Ab) are emerging serologic markers in rheumatoid arthritis (RA). Anti-CarP Ab has a controversial diagnostic utility in RA but may…
Abstract Number: 0490 • ACR Convergence 2025
Infection Risks Associated with Monotherapy and Combination Therapies Using Biological or Targeted – DMARD in RA: A Systematic Review and Network Meta-analysis
Li Liu¹, Xue-Mei Zhang¹, Zhi-Chun Gu¹ and Jia Li², ¹Ren Ji Hospital, Shanghai Jiao Tong University School Of Medicine, Pu Dong Xin Qu, Shanghai, China (People's Republic), ²Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic)
Background/Purpose: This study aimed to evaluate the infection risks in patients with rheumatoid arthritis (RA) treated with biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs),…
Abstract Number: 1732 • ACR Convergence 2025
Incidence of Flares in Pre-existing Rheumatologic Diseases Among Patients with Solid Tumors Undergoing Cancer Immunotherapy: A Systematic Review and Meta-analysis
Takemichi Matsui¹, Kenji Yamada², Toshiaki Takahashi³, Yoshito Nishimura⁴ and Yu Fujiwara⁵, ¹Department of Medicine, Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY, ²Department of Allergy and Rheumatology, Kameda Medical Center, Chiba, Japan, ³Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, ⁴Division of Hematology/Oncology, Mayo Clinic, Rochester, MN, ⁵Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Background/Purpose: Immune checkpoint inhibitors (ICIs) have become essential in cancer treatment, offering significant survival benefits across various malignancies. However, ICIs can cause immune-related Adverse Events…
Abstract Number: 0334 • ACR Convergence 2025
Diagnostic Test Accuracy of Ultrasound for Detecting Knee Osteoarthritis: A Systematic Review and Meta-Analysis
Mohamed Abdelsalam¹, Hadeer Hafez², Maryam Lasheen³, Bassant Elaraby Elsayed Badwy⁴, Omar Sameh Nabil El Sedafy¹, Menat Alla Ayman Ali Mahdy⁴, Hazem E. Mohammed⁵ and Mohamed Reda Awad⁶, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²⁶th October University, ⁶ october, Al Jizah, Egypt, ³Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, ⁴Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ⁵Faculty of Medicine, Assiut university, Assiut, Egypt, assyut, Asyut, Egypt, ⁶Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt
Background/Purpose: Ultrasound (US) is an emerging, promising imaging modality offering a safe, radiation-free, and cost-effective option for diagnosing and assessing structural changes in knee osteoarthritis…
Abstract Number: 1685 • ACR Convergence 2025
The Sjögren’s Tool for Assessing Response (STAR) demonstrates its ability to accurately detect treatment efficacy in 11 recent RCTs in Sjögren’s disease
Raphaele Seror¹, Gabriel Baron², Elodie Perrodeau³, Alena Piatrova⁴, Hendrika Bootsma⁵, Simon Bowman⁶, Jacques-eric GOTTENBERG⁷, Divi Cornec⁸, michele Bombardieri⁹, Suzanne Arends¹⁰, Benjamin A. Fisher¹¹, Wolfgang Hueber¹², Antoine Sreih¹³, Antonia Christodoulou¹⁴, Andre van Maurik¹⁵, Joel van Roon¹⁶, Valerie Devauchelle¹⁷, Peter Gergely¹⁸, Xavier Mariette¹⁹ and Raphael Porcher²⁰, ¹Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, ²Hôtel-Dieu, Université Paris Cité,, Paris, France, ³Université Paris Descartes Sorbonne Paris Cité, Paris, France, ⁴Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., Paris, Ile-de-France, France, ⁵UMCG, Groningen, Netherlands, ⁶University Hospitals Birmingham, Birmingham, United Kingdom, ⁷Hautepierre Hospital, STRASBOURG, Alsace, France, ⁸Departement of Rhumatology, CHU Brest, Université de Brest, INSERM UMR¹²²⁷: LBAI, Brest, France, Brest, France, ⁹Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, UK, London, United Kingdom, ¹⁰University Medical Center Groningen, Groningen, Netherlands, ¹¹King’s College London, London, UK; Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK, Birmingham, United Kingdom, ¹²Novartis Pharmaceuticals, Basel, Switzerland, ¹³Cullinan Therapeutics, New York, NY, ¹⁴BMS, Princeton, NJ, ¹⁵GlaxoSmithKline, Stevenage, United Kingdom, ¹⁶Center of Translational Immunology, Department of Immunology and Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht PO BOX ⁸⁵⁵⁰⁰, ³⁵⁰⁸ GA, Netherlands, Utrecht, Netherlands, ¹⁷UBO, Brest, France, ¹⁸Novartis Biomedical Research, Basel, Switzerland, ¹⁹Université Paris-Saclay, Le Kremlin Bicetre, France, ²⁰Université Paris Cité and Université Sorbonne Paris Nord, INSERM, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), Paris, France, Paris, France
Background/Purpose: Performance of the recently developed composite responder index STAR is highly awaited. We conduscted this study to evaluate the performance of STAR in previously…
Abstract Number: 0333 • ACR Convergence 2025
Diagnostic Test Accuracy of Artificial Intelligence in Early Diagnosis of Osteoarthritis: A Systematic Review and Meta-Analysis of 45,588 Knees
Mohamed Abdelsalam¹, Hadeer Hafez², Omar Sameh Nabil El Sedafy¹, Nourhan Abouelella³, Ahmed Abdulhafeez Hamza³, Omnia Samy El-Sayed⁴, Mohamed Reda Awad⁵, Gihan Omar³ and Hazem E. Mohammed⁶, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²⁶th October University, ⁶ october, Al Jizah, Egypt, ³Faculty of Medicine, Misr University for Science and Technology, ⁶ october, Al Jizah, Egypt, ⁴Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ⁵Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt, ⁶Faculty of Medicine, Assiut university, Assiut, Egypt, assyut, Asyut, Egypt
Background/Purpose: Artificial intelligence (AI) rapid advancement opens new opportunities in the field of rheumatology. With better imaging, AI may help find early osteoarthritic changes that…
Abstract Number: 1581 • ACR Convergence 2025
The Overall Prevalence and Associated Disease Characteristics of Calcinosis in Systemic Sclerosis: a Systematic Review and Meta-analysis
Marie-Elise Martel¹, Zélie Guitton², Aurélien Chepy¹, SEBASTIEN SANGES³, Eric Hachulla⁴, David Launay¹ and Vincent Sobanski⁵, ¹Univ. Lille, Inserm, CHU Lille, U¹²⁸⁶ - INFINITE - Institut de Recherche Translationnelle en Inflammation, Lille, France., Lille, France, ²CH Lens, Lens, France, ³Medecine Interne CHRU Lille, Lille, France, ⁴University of Lille, LILLE, France, ⁵Université de Lille, Lille, France
Background/Purpose: Calcinosis is a high-burden, key manifestation of systemic sclerosis (SSc), with a challenging therapeutic management. Yet, its precise prevalence and association with SSc charcateristics…
Abstract Number: 0332 • ACR Convergence 2025
Safety, Short- and Long-Term Efficacy of Methotrexate in Osteoarthritis: A Systematic Review and Meta-Analysis
Mohamed Abdelsalam¹, Maryam Lasheen², Hadeer Hafez³, Bassant Elaraby Elsayed Badwy⁴, Omar Sameh Nabil El Sedafy¹ and Mohamed Reda Awad⁵, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, ³⁶th October University, ⁶ october, Al Jizah, Egypt, ⁴Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ⁵Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt
Background/Purpose: Methotrexate (MTX), traditionally used for inflammatory conditions like rheumatoid arthritis, has well-established anti-inflammatory properties, recently gained interest as a potential therapeutic option for osteoarthritis…
Abstract Number: 1546 • ACR Convergence 2025
Tacrolimus Versus Voclosporin for Active Lupus Nephritis: A Comparative Meta-analysis of Renal Response
Urvi Zala¹ and Rushi Patel², ¹Loyola MacNeal Hospital, Berwyn, IL, Oak Park, IL, ²Baptist Hospitals of Southeast Texas, Beumont, TX
Background/Purpose: Lupus nephritis (LN) is seen in approximately 40–60 % of patients with systemic lupus erythematosus (SLE) and contributes significantly to morbidity and mortality in…
Abstract Number: 0331 • ACR Convergence 2025
Safety and Efficacy of Colchicine in Osteoarthritis: A Systematic Review and Meta-Analysis of 6,965 Patients
Mohamed Abdelsalam¹, Bassant Elaraby Elsayed Badwy², Menat Alla Ayman Ali Mahdy², Maryam Lasheen³, Hadeer Hafez⁴, Omar Sameh Nabil El Sedafy¹ and Mohamed Reda Awad⁵, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ³Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, ⁴⁶th October University, ⁶ october, Al Jizah, Egypt, ⁵Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt

Background/Purpose: Osteoarthritis (OA) is the most common joint disease, that leads to significant pain and affects quality of life, particularly in older adults. Current treatments…
Abstract Number: 1510 • ACR Convergence 2025
Biomarker landscape for neuropsychiatric involvement in patient with systemic lupus erythematosus
Sitian Zang¹, Ranran Yao² and Zhanguo Li³, ¹Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China (People's Republic), ²Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China (People's Republic), ³Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, Beijing, Beijing, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease result in substantial organs or systems damage or even fatal. The estimated number of global…
Abstract Number: 0319 • ACR Convergence 2025
Glucagon-like Peptide-1 Receptor Agonists in Management of Knee Osteoarthritis: A Meta-Analysis
Danielle Madison¹, Adriana Morales Rivera², Dylon Collins², Isabel Lam², Daniel Khokhar², Garrett Snyder², Anthony Thompson², Mark Soliman², Daniela Carralero Somoza² and Michael Sabina², ¹Lakeland Regional Medical Center, Lakeland, FL, ²Lakeland Regional Medical Center, Lakeland
Background/Purpose: Knee osteoarthritis (KOA) is a leading cause of disability and the most common rheumatological condition worldwide. Weight management has been recognized as a key…
Abstract Number: 1502 • ACR Convergence 2025
Prevalence and Associated Factors of Autoimmune Hepatitis and Primary Sclerosing Cholangitis in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Bisma Shaikh¹, Sarfaraz Hasni² and Omer Pamuk³, ¹Jinnah Sindh Medical University, Karachi, Pakistan, ²NIH/NIAMS, Bethesda, MD, ³University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune, chronic disorder characterized by multi-system organ involvement. The hepatic involvement in SLE is categorized as a primary…
Abstract Number: 0258 • ACR Convergence 2025
Performance characteristics of anti-Collagen II antibodies for diagnosing inflammatory and non-inflammatory diseases: a systematic review and meta-analysis
Karyssa Stonick¹, Marcela ferrada², Alice Fike³, Kaitlin Quinn³, Benjamin Turturice³, Casey Stein⁴ and Peter Grayson⁵, ¹National Insitute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ²University of Maryland, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁴NIAMS, NIH, Chevy Chase, MD, ⁵National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: Anti-collagen II (Col2) antibodies have been clinically and experimentally associated with relapsing polychondritis (RP), rheumatoid arthritis (RA), and other diseases. Whether anti-Col2 antibodies are…
Abstract Number: 0474 • ACR Convergence 2024
Association Between Rheumatoid Arthritis and Survival After Cancer: A Systematic Literature Review and Meta-analysis
Joshua Hsieh¹, Avneet Kaur², Hemant Khandelia³, Teresa Jewell⁴, Aman Singh⁵, Lauren Barkley⁶, Ishan Bansal⁷, Simmi Oberoi⁸ and Namrata Singh⁹, ¹Lakeside High School, Seattle, WA, ²SUNY Upstate, Buffalo, NY, ³AIIMS, New Delhi, Delhi, India, ⁴University of Washington, Seattle, WA, ⁵Rajindra Hospital, Patiala, Punjab, India, ⁶Brandeis University, Boston, MA, ⁷Yale University, New Haven, CT, ⁸Rajindra Hospital, New Delhi, India, ⁹University of Washington, Bellevue, WA
Background/Purpose: Increasing evidence suggests that inflammation, a hallmark of rheumatoid arthritis (RA), is associated with an elevated risk of cancer and can influence cancer outcomes.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].